Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Zacharon Pharmaceuticals
About
Zacharon Pharmaceuticals employs its glycobiology expertise to develop a new class of human therapeutics targeting glycans.
- 1 - 10
Highlights
Details
- Last Funding Type
- Grant
- Industries
- Biotechnology,Developer Platform,Health Care,Therapeutics
- Founded date
- Jan 1, 2004
- Number Of Employee
- 1 - 10
- Operating Status
- Close
Zacharon Pharmaceuticals is leveraging unique glycobiology expertise to develop an entirely new class of human therapeutics targeting glycans. Zacharon was incorporated in 2004 and has received initial funding through NIH grants and individual investors. Series A financing was more recently provided by Avalon Ventures, a long-standing San Diego-based venture capital firm with a focus on early stage life science companies. With this strong financial backing and innovative drug development platform in place, Zacharon is developing an entirely new class of human therapeutics addressing substantial unmet needs.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 25, 2008 | Grant | — | 1 |
National Institutes of Health
|
— | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Institutes of Health
|
Yes | Grant |
